CClinicalTrials.gg
Not yet recruitingNCT06762652RESCUEUpdated Jan 7, 2025

ImpRovEd Care After eSophageCtomy Using an Algorithm for postoperativE Complications - RESCUE Trial

An interventional study of Wash-in period and Algorithm-based care in Diagnosis and Treatment of Complications After Esophagectomy, sponsored by Radboud University Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
1,050
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the RESCUE-trial is to investigate whether implementation of a consensus-based clinical care algorithm to standardize diagnosis and management of postoperative complications reduces 90-day mortality, ICU (re)admission and surgical interventions after esophagectomy for esophageal cancer.

02

Conditions studied

  • Diagnosis and Treatment of Complications After Esophagectomy

Keywords

  • diagnosis
  • treatment
  • complications
  • esophagectomy
03

In context

Postoperative Complications

1,233 studies on the registry are indexed under Postoperative Complications; 292 are open to participants now.

This study's planned enrollment of 1,050 is above the median of 119 across 689 interventional studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  1. Age ≥ 18 years
  2. Histologically proven esophageal or gastro-esophageal junction carcinoma (cT1-4aN0-3M0)
  3. Scheduled to undergo curatively-intended esophagectomy with gastric tube reconstruction. All techniques (i.e. minimally invasive, robotic, hybrid, open) and approaches (i.e. transthoracic, transcervical, transhiatal) of esophagectomy are suitable for inclusion.
  4. Ability to provide written informed consent

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. Emergency resection
  2. Patients who underwent (additional) total gastrectomy
  3. Patients who underwent reconstruction using colonic or jejunal interposition
  4. Patients in whom no anastomosis is created during resection
  5. Secondary malignancy which determines prognosis
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
1,050 participants (estimated)

Study arms

  • Active comparator
    Usual Care

    During the control period, (participating) patients will receive usual postoperative care. Postoperative care, including diagnosis and management of postoperative complications, will be performed in line with local standards and/or protocols. For diagnosis of complications, physicians may perform laboratory tests such as CRP or leucocyte count, and diagnostic imaging such as CT-scan, X-ray or endoscopy. For treatment of complications, conservative, radiological, endoscopic and surgical treatments are often applied.

    Other: Wash-in period · Diagnostic Test: Algorithm-based care

Interventions

  • OtherWash-in period

    The goal of the wash-in period between the control and intervention period is to intensively educate and train physicians to use the algorithm as intended during daily postoperative care. The coordinating investigator along with the local principal investigator will be responsible for this training. Training will be performed in a standardized approach in order to guarantee uniformity across centres.

  • Diagnostic testAlgorithm-based care

    During the intervention period, (participating) patients will receive algorithm-based care. The RESCUE algorithm is a consensus-based clinical care algorithm developed to standardize postoperative care. The algorithm includes the same modalities as applied in usual care, and does not include novel/experimental modalities, but rather offers a novel, standardized approach to guide the use of common modalities during postoperative care. The daily objective evaluation of patients' condition, vital signs and biochemical parameters is thought to aid early diagnosis of complications after esophagectomy which enables treatment before systemic symptoms become apparent and prevent development of sepsis. Physicians are always allowed to deviate from the RESCUE, but reasons for deviating will be recorded.

06

What researchers measure

Primary outcomes

  1. Severe complications

    The primary outcome measure is the incidence of severe complications (i.e. Clavien-Dindo ≥ 3b). Severe complications are defined as a composite endpoint with one or more of the following criteria within 90 days after esophagectomy: 1. The complication was treated under general anaesthesia. 2. Postoperative mortality. 3. Escalation of care due to new onset or progressive organ failure (i.e. patients requiring vasopression, dialysis, (re-)intubation, (re)admission to a medium care or intensive care unit).

    Time frame: 90 days

Secondary outcomes

  1. General quality of life

    General quality of life, as measured using the validated EuroQol EQ-5D-5L questionnaire. Assessment will be performed at 6 weeks and 3, 6 and 12 months.

    Time frame: 6 weeks, and 3, 6, and 12 months after esophagectomy

  2. Time to functional recovery

    Time to functional recovery, defined as when a patient does not need intravenous fluid, has adequate pain control with oral analgesia (Numeric Rating Scale ≤4), restored mobility to an independent level (e.g. walk to the toilet with(out) walking aids and transfer bed/chair) or back to the previous functioning level of mobilization, sufficient caloric intake (minimum of 50% of the required calories), no signs of an active infection (no fever and declining CRP levels).

    Time frame: 90 days after esophagectomy

  3. Comprehensive Complications index

    Comprehensive Complications Index, a measure for the severity of all complications together.

    Time frame: 90 days after esophagectomy

  4. Failure to rescue

    Failure to rescue, defined as the rate of mortality in patients with a complication within 90-days after esophagectomy.

    Time frame: 90 days after esophagectomy

  5. Length of hospital (intensive care unit) stay

    Length of hospital and ICU stay, defined as the amount of days the patient stays in the ICU and in the hospital during 90 days postoperatively.

    Time frame: 90 days after esophagectomy

  6. Succes of algorithm implementation

    succes of implementation (i.e. proportion of patients' days in which the algorithm was not followed)

    Time frame: 90 days after esophagectomy

  7. Economic evaluation

    Cost-efficacy analysis will be performed from a societal perspective, including both medical and non-medical costs. Economic evaluation will be performed at 12 months follow-up. Medical resource use will be recorded from hospital records, including length of stay, laboratory and diagnostics use and treatment of complications. Medical resource use as well as out-of-pocket expenses will be recorded using iMTA Medical Consumption Questionnaire (iMCQ). \[26\] Resource use will be multiplied by associated unit costs to obtain total costs. Standard cost prices from the 'Dutch Guidelines for Cost Analyses' and www.medicijnkosten.nl will be used. Volumes of care will be multiplied by the cost price of each volume to calculate costs.

    Time frame: 3,6 and 12 months after esophagectomy

  8. Productivity losses

    Productivity losses will be measured using the iMTA Productivity Cost Questionnaire (iPCQ).

    Time frame: 3,6 and 12 months after esophagectomy

  9. Budget Impact Analysis

    Budget Impact Analysis (BIA) will be performed to assess the financial consequences of implementing the algorithm-based care, wherein the internationally accepted principles of ISPOR for the design, implementation and reporting of the BIA will be used. The third party payer perspective will be adopted to inform a business case for reimbursement companies.

    Time frame: 3,6 and 12 months after esophagectomy

  10. Cancer-specific quality of life

    Cancer-specific quality of life, as measured using the validated EIRTC QLQ-C30 questionnaire. Assessment will be performed at 6 weeks and 3, 6 and 12 months.

    Time frame: 6 weeks, and 3, 6, and 12 months after esophagectomy

  11. Esophageal cancer-specific quality of life

    Esophageal cancer-specific quality of life, as measured using the validated EORTC QLQ-OG25 questionnaire. Assessment will be performed at 6 weeks and 3, 6 and 12 months.

    Time frame: 6 weeks, and 3, 6, and 12 months after esophagectomy

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — This concerns a conceptual registration.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06762652
Lead sponsor
Radboud University Medical Center
Collaborators
Catharina Ziekenhuis Eindhoven, Erasmus Medical Center, University Medical Center Groningen, Hospital Group Twente (ZGT), Antoni van Leeuwenhoek Hospital, Leiden University Medical Center, Elisabeth-TweeSteden Ziekenhuis, medical center leeuwarden, Zuyderland Medical Centre, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Reinier de Graaf Groep, Gelre Hospitals, UMC Utrecht
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jan 7, 2025

Study contacts

Jobbe M.G. Lemmens, MD
Contact
Jobbe.Lemmens@radboudumc.nl
0652331762
Gijs van Dongen, MD
Contact
gijs.vandongen@radboudumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion